Medifast (NYSE:MED) Issues Q2 2026 Earnings Guidance

Medifast (NYSE:MED) updated its second quarter 2026 earnings guidance on Monday. The company provided EPS guidance of -1.000–0.500 for the period, compared to the consensus EPS estimate of -0.430. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $75.0 million. Medifast also updated its FY 2026 guidance to -2.750–1.550 EPS.

Analyst Ratings Changes

Several brokerages recently commented on MED. Stephens dropped their price objective on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 19th. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $12.00.

Medifast Price Performance

Shares of MED traded up $2.57 during midday trading on Tuesday, hitting $13.20. The stock had a trading volume of 285,525 shares, compared to its average volume of 241,529. The company has a 50 day simple moving average of $10.41 and a two-hundred day simple moving average of $11.10. Medifast has a twelve month low of $9.22 and a twelve month high of $15.46. The firm has a market cap of $145.64 million, a price-to-earnings ratio of -7.65 and a beta of 0.55.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.36. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The firm had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Analysts forecast that Medifast will post -2 EPS for the current fiscal year.

Insider Activity

In other news, CEO Daniel R. Chard purchased 17,678 shares of the company’s stock in a transaction on Friday, March 20th. The shares were purchased at an average price of $10.11 per share, with a total value of $178,724.58. Following the purchase, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at $178,724.58. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.70% of the stock is owned by corporate insiders.

More Medifast News

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Medifast reported EPS of ($0.19) vs. consensus ($0.55) and revenue of $76.0M vs. ~$69.2M expected; the outperformance likely reassured investors about current sales execution. Read More.
• Positive Sentiment: Healthy balance sheet and coach metrics — cash, cash equivalents and investments of $168.9M, no debt, 14,000 independent active earning coaches and revenue per active coach of $5,432 provide liquidity and optionality while the business stabilizes. Read More.
• Neutral Sentiment: Earnings call color — management described rising coach productivity even “amid sharp decline” in some underlying metrics; the call struck a cautious tone that mixed operating improvements with ongoing headwinds. Investors will want to parse the transcript for trend details. Read More.
• Neutral Sentiment: Full materials available — call transcript and slide deck were posted (useful for tracking management’s levers for recovery and unit economics). Read More. • Read More.
• Negative Sentiment: Weaker near‑term guidance — Q2 EPS guide of ($1.00) to ($0.50) and revenue guidance $60M–$80M came in below consensus; FY 2026 EPS guide of ($2.75) to ($1.55) is also weaker than street expectations, signaling continued pressure ahead. Read More.
• Negative Sentiment: Profitability remains challenged — Q1 produced a net loss ($2.1M), negative net margin and negative ROE; analysts still model a loss for the year, which keeps downside risk if top‑line recovery stalls. Read More.

Institutional Trading of Medifast

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. acquired a new stake in shares of Medifast in the second quarter valued at about $200,000. Barclays PLC increased its position in shares of Medifast by 10.6% in the fourth quarter. Barclays PLC now owns 16,769 shares of the specialty retailer’s stock valued at $179,000 after acquiring an additional 1,608 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Medifast in the second quarter valued at about $161,000. Wells Fargo & Company MN increased its position in shares of Medifast by 36.9% in the fourth quarter. Wells Fargo & Company MN now owns 14,169 shares of the specialty retailer’s stock valued at $151,000 after acquiring an additional 3,821 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in shares of Medifast in the third quarter valued at about $144,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.